Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


LAB Act Included In Must-Pass, US 2020 Appropriations Bill Legislation Due To Be Signed By 20 December

Executive Summary

The US Congress and President Donald Trump are expected to clear and sign off on the Laboratory Access for Beneficiaries Act favored by the clinical laboratory industry and manufacturers of in vitro test kits, as part of a must-pass appropriations bill intended to keep the US government open and funded for the balance of the 2020 fiscal year.

You may also be interested in...

After Seven Years Device Tax Repeal Looks Certain

US lawmakers have agreed on a bipartisan budget to prevent a government shutdown that includes repealing the medical device tax. If all goes according to plan, the bill -- which was approved by the House on 17 December and is now headed to the Senate -- is expected to be on the president’s desk for signing by the end of the week.

Clinical Lab Group Gets Go-Ahead On Medicare Payment Suit

The American Clinical Laboratory Association (ACLA) may proceed with a lawsuit against the US Department of Health and Human Services, an appeals court has ruled. The suit alleges that the agency is setting lab test payment rates unfairly.

White House To Deliver 25 Million Face Masks To Low-Income Americans

The White House will be spending $86m to provide tens of millions of coronavirus masks to poorer American households.


Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts